

April 28, 2017



## **BioSig Technologies to Present at Joseph Gunnar PIONEERS 2017 Conference on May 2**

Minneapolis, MN, April 28, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the \$4 billion electrophysiology (EP) marketplace, today announced that its Director of Business Development, Josh Conroy will present at PIONEERS 2017, presented by Joseph Gunnar & Co., on Tuesday, May 2nd at 3:00 PM EDT in the Lotus West room at the Mandarin Oriental Hotel in New York City.

During the conference, Mr. Conroy will deliver the Company's corporate presentation and discuss key milestones. The Company will also be available for one-on-one meetings. To arrange a meeting, please email Lora Mikolaitis at [lmikolaitis@biosigtech.com](mailto:lmikolaitis@biosigtech.com).

### **About Joseph Gunnar & Co.**

Joseph Gunnar & Co., LLC was founded in 1997 as a full-service broker-dealer dedicated to assisting investors achieve their financial goals by providing a full array of investment products and vehicles to private and corporate clients. They pride themselves on personalized service not often available at many "bulge bracket" firms; and are a member of FINRA & SIPC. The Joseph Gunnar PIONEERS 2017 Conference will include company presentations, 1x1 investor meetings and networking opportunities.

### **About BioSig Technologies**

BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the \$4 billion electrophysiology (EP) marketplace ([www.biosigtech.com](http://www.biosigtech.com)). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market.

The PURE EP System is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig's main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance and

CE Mark for the PURE EP System.

## **Forward-looking Statements**

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates.. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at <http://www.sec.gov>. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Relations:  
Lora Mikolaitis  
BioSig Technologies, Inc.  
[lmikolaitis@biosigtech.com](mailto:lmikolaitis@biosigtech.com)  
310.948.7200



Source: BioSig Technologies, Inc.